HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: The D:A:D cohort study

Antiviral Therapy

Volumn 15, Issue 8, 2010, Pages 1077-1086

  Weber, Rainer ^a   Sabin, Caroline ^b   Reiss, Peter ^c   De Wit, Stephane ^d   Worm, Signe W ^e   Law, Matthew ^f   Dabis, Francois ^g   Monforte, Antonella D'Arminio ^h   Fontas, Eric ⁱ   El Sadr, Wafaa ^j   Kirk, Ole ^k   Rickenbach, Martin ^l   Phillips, Andrew ^b   Ledergerber, Bruno ^a   Lundgren, Jens ^k  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c STICHTING HIV MONITORING   (Netherlands)

^d SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g INSERM   (France)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^j Och Spine at New York Presbyterian Hospitals   (United States)

^k CHIP ^*

^l SHCS Data Center   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEART INFARCTION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; STROKE;

ADULT; AUSTRALIA; COHORT STUDIES; EUROPE; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS C; HEPATITIS C ANTIBODIES; HIV INFECTIONS; HUMANS; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; POISSON DISTRIBUTION; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; STROKE; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; UNITED STATES;

EID: 78650972372     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1681     Document Type: Article

References (58)

1. Bedimo R, Ghurani R, Nsuami M, et al. Lipid abnormalities in HIV/hepatitis C virus-coinfected patients. HIV Med 2006; 7:530-536.
2. Collazos J, Mayo J, Ibarra S, et al. Hyperlipidemia in HIV-infected patients: the protective effect of hepatitis C virus co-infection. AIDS 2003; 17:927-929.
3. Floris-Moore M, Howard AA, Lo Y, et al. Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. AIDS Patient Care STDS 2007; 21:479-491.
4. Dai CY, Chuang WL, Ho CK, et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol 2008; 49:9-16.
5. Reingold J, Wanke C, Kotler D, et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008; 48:142-148.
6. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997;96:4095-4103.
7. Fabricant CG, Fabricant J, Litrenta MM, et al. Virus-induced atherosclerosis. J Exp Med 1978; 148:335-340.
8. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97:633-636.
9. Mayr M, Kiechl S, Willeit J, et al. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 2000; 102:833-839.
10. Zhu J, Nieto FJ, Horne BD, et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 2001; 103:45-51.
11. Zhu J, Quyyumi AA, Norman JE, et al. The possible role of hepatitis A virus in the pathogenesis of atherosclerosis. J Infect Dis 2000; 182:1583-1587.
12. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430-436.
13. O'Connor S, Taylor C, Campbell LA, et al. Potential infectious etiologies of atherosclerosis: a multifactorial perspective. Emerg Infect Dis 2001; 7:780-788.
14. Ludewig B, Freigang S, Jaggi M, et al. Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model. Proc Natl Acad Sci U S A 2000; 97:12752-12757.
15. Nicoletti A, Kaveri S, Caligiuri G, et al. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998; 102:910-918.
16. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-1735.
17. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
18. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients -association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-1193.
19. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417-1426.
20. Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007; 45:111-119.
21. De Wit S, Sabin C, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31:1224-1229.
22. The SMART/INSIGHT and DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22:F17-F24.
23. Hsue PY, Hunt PW, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009; 23:2021-2027.
24. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23:1059-1067.
25. de Larranaga GF, Wingeyer SD, Puga LM, et al. Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment. Eur J Clin Microbiol Infect Dis 2006; 25:98-103.
26. The Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
27. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90:583-612.
28. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009; 338:b2393.
29. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000;11:561-570.
30. Weber R, Sabin CA, Reiss P, et al. Hepatitis virus co-infections and risk of diabetes mellitus and myocardial infarction in HIV-infected persons: The D:A:D Study. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 1082.
31. Ishizaka N, Ishizaka Y, Takahashi E, et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002;359:133-135.
32. Ishizaka Y, Ishizaka N, Takahashi E, et al. Association between hepatitis C virus core protein and carotid atherosclerosis. Circ J 2003; 67:26-30.
33. Fukui M, Kitagawa Y, Nakamura N, et al. Hepatitis C virus and atherosclerosis in patients with type 2 diabetes. JAMA 2003; 289:1245-1246.
34. Vassalle C, Masini S, Bianchi F, et al. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 2004; 90:565-566.
35. Tien PC, Schneider MF, Cole SR, et al. Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the women's interagency HIV study. AIDS 2009; 23:1781-1784.
36. Arcari CM, Nelson KE, Netski DM, et al. No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis 2006; 43:e53-e56.
37. Völzke H, Schwahn C, Wolff B, et al. Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. Atherosclerosis 2004; 174:99-103.
38. Butt AA, Xiaoqiang W, Budoff M, et al. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49:225-232.
39. Freiberg MS, Cheng DM, Kraemer KL, et al. The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals. AIDS 2007; 21:193-197.
40. Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 2010; 11:462-468.
41. Ishizaka N, Ishizaka Y, Takahashi E, et al. Increased prevalence of carotid atherosclerosis in hepatitis B virus carriers. Circulation 2002; 105:1028-1030.
42. Kiechl S, Egger G, Mayr M, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001; 103:1064-1070.
43. Momiyama Y, Ohmori R, Kato R, et al. Lack of any association between persistent hepatitis B or C virus infection and coronary artery disease. Atherosclerosis 2005;181:211-213.
44. Tong DY, Wang XH, Xu CF, et al. Hepatitis B virus infection and coronary atherosclerosis: results from a population with relatively high prevalence of hepatitis B virus. World J Gastroenterol 2005; 11:1292-1296.
45. Sung J, Song YM, Choi YH, et al. Hepatitis B virus seropositivity and the risk of stroke and myocardial infarction. Stroke 2007; 38:1436-1441.
46. Petty GW, Duffy J. Houston J, 3rd. Cerebral ischemia in patients with hepatitis C virus infection and mixed cryoglobulinemia. Mayo Clin Proc 1996; 71:671-678.
47. Delluc A, Saadoun D, Ghillani-Dalbin P, et al. Cryofibrinogen in patients with hepatitis C virus infection. Am J Med 2008; 121:624-631.
48. Capra F, De Maria E, Lunardi C, et al. Serum level of soluble intercellular adhesion molecule 1 in patients with chronic liver disease related to hepatitis C virus: a prognostic marker for responses to interferon treatment. J Infect Dis 2000; 181:425-431.
49. Cacoub P, Ghillani P, Revelen R, et al. Anti-endothelial cell auto-antibodies in hepatitis C virus mixed cryoglobulinemia. J Hepatol 1999; 31:598-603.
50. Sumida Y, Nakashima T, Yoh T, et al. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J Hepatol 2000; 33:616-622.
51. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122:366-375.
52. Li K, Prow T, Lemon SM, et al. Cellular response to conditional expression of hepatitis C virus core protein in Huh7 cultured human hepatoma cells. Hepatology 2002;35:1237-1246.
53. Sansonno D, Tucci FA, Troiani L, et al. Increased serum levels of the chemokine CXCL13 and upregulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis. Blood 2008; 112:1620-1627.
54. Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84:313-322.
55. Agnello V, Abel G. Localization of hepatitis C virus in cutaneous vasculitic lesions in patients with type II cryoglobulinemia. Arthritis Rheum 1997; 40:2007-2015.
56. Mason A, Theal J, Bain V, et al. Hepatitis B virus replication in damaged endothelial tissues of patients with extrahepatic disease. Am J Gastroenterol 2005; 100:972-976.
57. Meade TW, Stirling Y, Thompson SG, et al. Carriers of hepatitis B surface antigen: possible association between low levels of clotting factors and protection against ischaemic heart disease. Thromb Res 1987; 45:709-713.
58. Marchesini G, Ronchi M, Forlani G, et al. Cardiovascular disease in cirrhosis - a point-prevalence study in relation to glucose tolerance. Am J Gastroenterol 1999; 94:655-662.